Senior Deals Analyst, Biomedtracker
Deanna has been tracking deal-making activity in the biopharma and medtech industries since 2000. She is currently a Senior Deals Analyst for Biomedtracker and had previously contributed to the Strategic Transactions deals database. Deanna authors a Quarterly Statistics article and other monthly trend pieces for In Vivo. She holds a Bachelor of Science degree from the University of Vermont..
Latest From Deanna Kamienski
In the top August alliance by deal value, Precision BioSciences licensed Imugene global rights to azercabtagene zapreleucel (azer-cel), its lead allogeneic anti-CD19 CAR T candidate for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future. Precision will receive $21m up front and is eligible for $8m upon successful completion of the Phase Ib dosing in the CAR T relapsed LBCL patient population. For azer-cel, Precision is eligible to receive up to $198m in additional milestone payments plus royalties. For each additional research program selected by Imugene, Precision is eligible for up to $145m in milestone payments and tiered royalties on net sales.
Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.
During Q2, biopharma merger and acquisition deal value reached $29bn and drew in $36.8bn in potential deal value from alliances. Device company M&A values reached $988m, while in vitro diagnostics and research tools players’ M&A activity totaled $450m.
During Q2, biopharmas brought in an aggregate $23.8bn in financing and device company fundraising totaled $2.4bn; while in vitro diagnostic firms and research tools players raised $684m.
Three $1bn+ alliances were penned in June. Topping the list was a potential $2.5bn deal under which Bausch & Lomb acquired Novartis’ Xiidra (lifitegrast ophthalmic solution) for signs and symptoms of dry eye disease; investigational compounds SAF312 (libvatrep) for chronic ocular surface pain and OJL332 for an undisclosed ophthalmic indication; plus rights to use the AcuStream delivery device in dry eye indications.
Four $1bn+ alliances were penned in May. Topping the list was a potential $2bn deal between Bliss Biopharmaceutical and Eisai for BB-1701, which is currently in Phase I/II studies in the US and China for various types of cancers. Both parties will conduct co-development activities related to BB-1701 through an option period. Should Eisai exercise its option, it would receive worldwide rights (excluding Greater China) to develop and commercialize BB-1701.